WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free. The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS. |
Chinese cities to see tourism peak in New Year's Day holidayTourists from China and Kazakhstan to enjoy mutual visaChina Honors Promise to Ensure Smooth Running of Chengdu Universiade: XiXi Says China to Work with Pakistan to Build CPEC into Exemplary Project of HighChinese mainland travelers to Hong Kong airport will be exempted from entry permitsXi Meets Guyanese PresidentChina Honors Promise to Ensure Smooth Running of Chengdu Universiade: XiKeeping focused vital against Guam, says Chinese midfielderHarry Kane ends England's long wait for a final appearance to end Schmeichel's heroicsHighlights of Australian Open women's singles first round